Medable Selected by GSK to Power Decentralized and Hybrid Clinical Trials
Medable selected by GSK to accelerate the delivery of new medicines and enable their clinical trials to be more inclusive and representative of all patient populations.
Medable announced that it has entered a four-year enterprise contract with GSK to enable decentralized clinical trials (DCTs) across their portfolio using the company’s DCT platform. Medable was selected by GSK to accelerate the delivery of new medicines and enable their clinical trials to be more inclusive and representative of all patient populations.
Read more about the new partnership
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
